Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | APAF1 | O14727 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MPO | P05164 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21411535 | 0.88 | KDM4E (0.63) | KDM4EMAPTPOLBKMT2AAPAF1 | |
| SCHEMBL3855611 | 0.87 | KDM4E (0.68) | KDM4EMAPTPOLBKMT2AAPAF1 | |
| SCHEMBL29212821 | 0.87 | KDM4E (0.68) | KDM4EMAPTPOLBKMT2AAPAF1 | |
| SCHEMBL3855614 | 0.87 | KDM4E (0.68) | KDM4EMAPTPOLBKMT2AAPAF1 | |
| SCHEMBL29787090 | 0.84 | KDM4E (0.64) | KDM4EMAPTPOLBKMT2AAPAF1 | |
| SCHEMBL28163928 | 0.84 | KDM4E (0.64) | KDM4EMAPTPOLBKMT2AAPAF1 | |
| SCHEMBL22384094 | 0.83 | KDM4E (0.67) | KDM4EMAPTPOLBKMT2AAPAF1 | |
| SCHEMBL31018783 | 0.83 | KDM4E (0.63) | KDM4EMAPTPOLBKMT2AAPAF1 | |
| SCHEMBL29212839 | 0.83 | KDM4E (0.63) | KDM4EMAPTPOLBKMT2AAPAF1 | |
| SCHEMBL31018781 | 0.83 | KDM4E (0.63) | KDM4EMAPTPOLBKMT2AAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746079-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | Bayer Aktiengesellschaft (DE) | 2020-12-09 | — | — | EP | claimed |
| WO-2019149637-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-08 | — | — | WO | claimed |
| US-10350206-B2 | Benzyl substituted indazoles as BUB1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-16 | — | — | US | claimed |
| US-20170305882-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | claimed |
| US-20170275269-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | claimed |
| US-20170273980-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | claimed |
| US-20170275270-A1 | BENZYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | claimed |
| EP-3194378-A1 | BENZYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-26 | — | — | EP | claimed |
| WO-2016041925-A1 | BENZYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-24 | — | — | WO | claimed |
| US-10350206-B2 | Benzyl substituted indazoles as BUB1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-16 | — | — | US | disclosed |
| US-20170305882-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20170275269-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170273980-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275270-A1 | BENZYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| WO-2016041925-A1 | BENZYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-24 | — | — | WO | disclosed |
| US-20150141431-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | CONCERT PHARMACEUTICALS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| EP-2413711-A1 | DIPEPTIDE AS FEEDSTUFF ADDITIVE | Evonik Degussa GmbH (DE) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010112365-A1 | DIPEPTIDE AS FEEDSTUFF ADDITIVE | EVONIK DEGUSSA GMBH (DE) | 2010-10-07 | — | — | WO | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20060100207-A1 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100207-A1 | Dihydropyridinone derivatives | TNNI3, DHPS, TNNT2 | KDM4E 1572/4885MAPT 4727/4885POLB 3029/4885 |
| US-20150141431-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | H1-5, MTX2, H1-4 | KDM4E 1034/4885MAPT 4507/4885POLB 2573/4885 |
| US-20170275270-A1 | BENZYL SUBSTITUTED INDAZOLES | UGT2B7, CYP3A43, CYP3A7 | KDM4E 2538/4885MAPT 1251/4885POLB 2816/4885 |
| US-10350206-B2 | Benzyl substituted indazoles as BUB1 inhibitors | BUB1, BUB1B, BUB3 | KDM4E 1627/4885MAPT 450/4885POLB 589/4885 |
| US-20170273980-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 INHIBITORS | BUB1, BUB1B, BUB3 | KDM4E 1627/4885MAPT 450/4885POLB 589/4885 |
| US-20170275269-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | BUB1, BUB1B, BUB3 | KDM4E 1582/4885MAPT 597/4885POLB 811/4885 |
| US-20170305882-A1 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS | BUB1, BUB1B, BUB3 | KDM4E 1582/4885MAPT 597/4885POLB 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.